Discovery
Clinical Pharmacology & Therapeutics (2007) 82, 740–744; doi:10.1038/sj.clpt.6100402; published online 31 October 2007
MF59 Is a Safe and Potent Vaccine Adjuvant for Flu Vaccines in Humans: What Did We Learn During Its Development?
D T O'Hagan1, A Wack1 and A Podda1
1Novartis Vaccines and Diagnostics Inc., Siena, Italy
Correspondence: DT O'Hagan, (derek.ohagan@novartis.com)
Abstract
The MF59 adjuvant has been included in a licensed influenza vaccine for a decade. Hence, we have a significant amount of clinical data to establish its potency and safety. We can now reassess our early preclinical studies and determine whether or not they were useful to predict human responses. The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Toll-free vaccines?Nature Biotechnology News and Views (01 Mar 2007)
Toll-free vaccines?Nature Biotechnology News and Views (01 Mar 2007)
